Novel inhibitors of factor X for use in cardiovascular diseases

Current Cardiology Reports

Volumn 2, Issue 5, 2000, Pages 395-404

  Spencer, Frederick A ^a   Becker, Richard C ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; ANTI COAGULANT PROTEIN 5, ANCYLOSTOMA CANINUM; ANTI-COAGULANT PROTEIN 5, ANCYLOSTOMA CANINUM; ANTISTASIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; FIBRINOLYTIC AGENT; FONDAPARINUX; HELMINTH PROTEIN; HORMONE; LOW MOLECULAR WEIGHT HEPARIN; NAPHTHALENE DERIVATIVE; OLIGOSACCHARIDE; PEPTIDE; PIPERIDINE DERIVATIVE; PROPIONIC ACID DERIVATIVE; TICK ANTICOAGULANT PEPTIDE;

ANIMAL; CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; HUMAN; LEECH; REVIEW;

ANIMALS; ANTITHROMBIN III; CARDIOVASCULAR DISEASES; FACTOR X; FACTOR XA; FIBRINOLYTIC AGENTS; HELMINTH PROTEINS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INVERTEBRATE HORMONES; LEECHES; NAPHTHALENES; OLIGOSACCHARIDES; PEPTIDES; PIPERIDINES; PROPIONIC ACIDS;

EID: 0034264509     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-000-0052-z     Document Type: Article

References (56)

1. Oler A, Whooley MA, Oler J, Grady D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996, 276:811-815.
2. Spencer FA, Ball SP, Zhang Q, et al.: Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by Factor-Xa neutralization. J Thromb Thrombolysis 2000, 9:223-228.
3. Ellis V, Scully ME, Kakkar VV: Inhibition of prothrombinase complex by plasma proteinase inhibitors. Biochemistry 1984, 23:5882-5887.
4. Barrowcliffe TW, Havercroft SJ, Kemball-Cook G, Lindahl U: The effect of Ca2+, phospholipid, and factor V on the anti-(factor Xa) activity of heparin and its high affinity oligosaccharides. Biochem J 1987, 243:31-37.
5. Cohen M, Demers C, Gurfinkel EP, et al.: A comparison of low molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997, 337:447-452.
6. Antman EM, McCabe CH, Gurfinkel EP, et al.: Enoxaparin prevents death and cardiac ischemic events in unstable Angina/Non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999, 100:1593-601.
7. Fragmin during Instability in Coronary Artery Disease (FRISC) study group: Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996, 347:561-568.
8. Choay J, Petitou M, Lormeau JC, et al.: Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high antifactor Xa activity. Biochem Biophys Res Commun 1983, 116:492-499.
9. Cadroy Y, Hanson SR, Harker LA: Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithormbin III in non-human primates. Thromb Haemost 1993, 70:631-635.
10. Herbert JM, Herault JP, Bernat A, et al.: Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide" (SR 90107/ORG 31540) and standard heparin. Circ Res 1996, 79:590-600.
11. Pislaru SV, Pislaru C, Zhu X, et al.: Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis. Thromb Haemost 1998, 79:1130-1135.
12. Boneu B, Necciari J, Cariou R, et al.: Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG 31540) with high affinity to antithrombin III in man. Thromb Haemost 1995, 74:1468-1473.
13. Verstraete M: New developments in antiplatelet and antithrombotic therapy. Eur Heart J 1995, 16(Suppl L):16-23.
14. Vuillemenot A, Schiele F, Memeveau N, et al.: Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent-a pilot study in the setting of coronary angioplasty. Thromb Haemost 1999, 81:214-220.
15. Coussement PK: SR9010A/ORG31540, a new synthetic pentasaccharide, as an adjunct to fibrinolysis in ST-elevation acute myocardial infarction: the PENTALYSE Study. Presented to the ACC Scientific Session 2000. March 15, 2000.
16. Herbert JM, Hérault JP, Bernat A, et al.: Biochemical and pharmacological properties of SANORG 32701: comparison with the "synthetic pentasaccharide" (SR 90107/ORG 31540) and standard heparin. Circ Res 1996, 79:590-600.
17. Herbert JM, Hérault JP, Bernat A, et al.: Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998, 91:4197-4205.
18. Bagdy D, Barabas É, Gráf L, et al.: Hirudin. Methods Enzymol 1976, 45:669-678.
19. Seemuller U, Meier M, Ohlsson K, et al.: Isolation and characterization of a low molecular weight inhibitor (of chymotrypsin and human granulocytic elastase and cathepsin G) from leeches. Hoppe-Seylers Zeitschrift fur Physiol Chem 1977, 358:1105-1117.
20. Malinconico SM, Katz JB, Budzynski AZ: Hementin - anticoagulant protease from the salivary gland of the leech Haementeria ghilaranii. J Lab Clin Med 1984, 103:44-58.
21. Kelen EMA, Rosenfeld G: Fibrinogenolytic substance (hementerin) of Brazilian blood-sucking leeches (Haementeria lutzi Pinto 1920). Haemostasis 1975, 4:51-64.
22. Tuszynski GP, Gasic TB, Gasic GJ: Isolation and characterization of antistasin: an inhibitor of metastasis and coagulation. J Biol Chem 1987, 262:9718-9723.
23. Dunwiddie C, Thornberry NA, Bull HG, et al.: Antistasin, a leech-derived inhibitor of factor Xa: kinetic analysis of enzyme inhibition and identification of the reactive site. J Biol Chem 1989, 264:16694-16699.
24. Nutt EM, Jain D, Lenny AB, et al.: Purification and characterization of recombinant antistasin: a leech-derived inhibitor of coagulation factor Xa. Arch Biochem Biophys 1991, 285:37-44.
25. Schaffer LW, Davidson JT, Vlasuk GP, et al.: Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons. Arterioscler Thromb 1992, 12:879-885.
26. Mellott MJ, Holahan MA, Lynch JJ, et al.: Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. Circ Res 1992, 70:1152-1160.
27. Dunwiddie CT, Nutt EM, Vlasuk GP, et al.: Anticoagulant efficacy and immunogenicity of the selective factor Xa inhibitor antistasin following subcutaneous administration in the rhesus monkey. Thromb Haemost 1992, 67:371-376.
28. Waxman L, Smith DE, Arcuri KE, Vlasuk GP: Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990, 248:593-596.
29. Lehman ED, Schaefer TF, Przysiecki CT, et al.: Large scale purification and characterization of recombinant tick anticoagulant peptide. J Chromatog 1992, 574:225-235.
30. Schaffer LW, Davidson JT, Vlasuk GP, Siegl PKS: Antithrombotic efficacy of recombinant tick anticoagulant peptide: a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991, 84:1741-1748.
31. Sitko GR, Ramjit DR, Stabilito II, et al.: Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide: comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992, 85:805-815.
32. Lynch Jr JJ, Sitko GR, Lehman ED, Vlasuk GP: Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model. Thromb Haemost 1995, 74:640-645.
33. Cappello M, Vlasuk GP, Bergum PW, Huang S, Hotez PJ: Ancylostoma caninum anticoagulant peptide: a hookwormderived inhibitor of human coagulation factor Xa. Proc Natl Acad Sci U S A 1995, 92:6152-6156.
34. Stanssens P, Bergum PW, Gansemans Y, et al.: Anticoagulant repertoire of the hookworm Ancylostoma canium. Proc Natl Acad Sci U S A 1996, 93:2149-2154.
35. Rote WE, Vlasuk GP: Evaluation of a novel small protein inhibitor of blood coagulation factor Xa in a porcine model of acute coronary artery thrombosis. Circulation 1995, 92(Suppl 1):2322.
36. Rebello SS, Blank HS, Rote WE, et al.: Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J Pharmacol Exp Ther 1997, 283:91-99.
37. Hara T, Yokoyama A, Ishihara H, et al.: DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994, 41:314-319.
38. Hara T, Yokoyama A, Tanabe K, et al.: DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1995, 74:635-639.
39. Morishima Y, Tanabe K, Terada Y, et al.: Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 1997, 78:1366-1371.
40. Wong PC, Crain Jr EJ, Nguan O, et al.: Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. Thromb Res 1996, 83:117-126.
41. Rogers KL, Chi L, Rapundalo ST, et al.: Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis. Basic Res Cardiol 1999, 94:15-22.
42. Yokoyama T, Kelly AB, Marzec UM, et al.: Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 1995, 92:485-491.
43. Murayama N, Tanaka M, Kunitada S, et al.: Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin Pharmacol Therapy 1999, 66:258-264.
44. Taniuchi Y, Sakai Y, Hisamichi N, et al.: Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemost 1998, 79:543-548.
45. Sato K, Kawasaki T, Hisamichi N, et al.: Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Brit J Pharmacol 1998, 123:92-96.
46. Sato K, Kawasaki T, Taniuchi Y, et al.: YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. Eur J Pharmacol 1997, 339:141-146.
47. Sato K, Kawasaki T, Hisamichi N, et al.: Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs (short commun.). Eur J Pharmacol 1998, 350:87-91.
48. Kawasaki T, Sato K, Sakai Y, et al.: Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb Haemost 1998, 79:410-416.
49. Kawasaki T, Sato K, Hirayama F, et al.: Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis. Thromb Haemost 1998, 79:859-64.
50. Sato K, Taniuchi Y, Kawasaki T, et al.: Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice. Jpn J Pharmacol 1998, 78:191-197.
51. Sato K, Taniuchi Y, Kawasaki T, et al.: Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats. Eur J Pharmacol 1998, 347:231-236.
52. Sato K, Kaku S, Hirayama F, et al.: Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time. Eur J Pharmacol 1998, 352:59-63.
53. Quan ML, Pruitt JR, Ellis CD, et al.: Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors. Bioorg Med Chem Lett 1997, 7:2813-2818.
54. Quan ML, Ellis CD, Liauw AY, et al.: Design and synthesis of isoxazoline derivatives as factor Xa inhibitors.2. J Med Chem 1999a, 42:2760-2773.
55. Quan ML, Liauw AY, Ellis CD, et al.: Design and synthesis of isoxazoline derivatives as factor Xa inhibitors.1. J Med Chem 1999b, 42:2752-2759.
56. Wong PC, Quan ML, Crain EJ, et al.: Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. J Pharmacol Exp Ther 2000, 292:351-357.